Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Articles by Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
4
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
5